[Tumor markers in renal cell carcinoma]

Area of Science:

• Oncology
• Clinical Chemistry
• Immunology

Context:

• Renal cell carcinoma (RCC) diagnosis and prognosis often rely on complex methods.
• Identifying reliable serological markers for RCC is crucial for early detection and management.
• This study investigates the utility of various biomarkers in RCC patients.

Purpose:

• To evaluate the diagnostic and prognostic value of erythrocyte sedimentation rate (ESR), lactase dehydrogenase (LDH), carcinoembryonic antigen (CEA), haptoglobin, fibrinogen, CH50, C3, C4, T-cell, B-cell, and phytohemagglutinin (PHA) in 82 renal cell carcinoma patients.
• To assess the correlation of these markers with tumor stage and patient prognosis.

Summary:

• Positive rates for ESR, fibrinogen, CEA, haptoglobin, C3, and C4 were significantly higher in advanced stages (III-IV) of RCC compared to early stages (I-II).
• Elevated levels of ESR, LDH, CEA, fibrinogen, haptoglobin, and CH50 were observed in RCC patients.
• ESR and fibrinogen demonstrated utility for screening, while ESR, CEA, haptoglobin, fibrinogen, and C3 aided in staging and prognosis estimation.

Impact:

• Serological markers like ESR and fibrinogen can serve as valuable tools for screening renal cell carcinoma.
• Specific biomarkers (ESR, CEA, haptoglobin, C3) can assist in determining tumor stage and predicting patient outcomes.
• This research contributes to the development of more accessible diagnostic and prognostic strategies for RCC.